vs
Side-by-side financial comparison of IOVANCE BIOTHERAPEUTICS, INC. (IOVA) and PLAYSTUDIOS, Inc. (MYPS). Click either name above to swap in a different company.
IOVANCE BIOTHERAPEUTICS, INC. is the larger business by last-quarter revenue ($86.8M vs $55.4M, roughly 1.6× PLAYSTUDIOS, Inc.). On growth, IOVANCE BIOTHERAPEUTICS, INC. posted the faster year-over-year revenue change (17.7% vs -18.3%). PLAYSTUDIOS, Inc. produced more free cash flow last quarter ($3.6M vs $-61.9M). Over the past eight quarters, IOVANCE BIOTHERAPEUTICS, INC.'s revenue compounded faster (1001.6% CAGR vs -15.6%).
Iovance Biotherapeutics, Inc. is a biopharmaceutical startup based in San Carlos, California. The company works to develop tumor-infiltrating lymphocyte (TIL) therapies against cancer.
PLAYSTUDIOS, Inc. develops and publishes free-to-play social and casual casino games for mobile, desktop and social platforms. It operates a loyalty rewards program that lets players redeem in-game achievements for real-world benefits including travel, dining and event tickets, serving markets across North America, Europe and Asia Pacific.
IOVA vs MYPS — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $86.8M | $55.4M |
| Net Profit | — | $-13.7M |
| Gross Margin | 67.4% | — |
| Operating Margin | -84.7% | -17.7% |
| Net Margin | — | -24.7% |
| Revenue YoY | 17.7% | -18.3% |
| Net Profit YoY | — | 38.9% |
| EPS (diluted) | — | $-0.12 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $86.8M | $55.4M | ||
| Q3 25 | $67.5M | $57.6M | ||
| Q2 25 | $60.0M | $59.3M | ||
| Q1 25 | $49.3M | $62.7M | ||
| Q4 24 | $73.7M | $67.8M | ||
| Q3 24 | $58.6M | $71.2M | ||
| Q2 24 | $31.1M | $72.6M | ||
| Q1 24 | $715.0K | $77.8M |
| Q4 25 | — | $-13.7M | ||
| Q3 25 | $-91.3M | $-9.1M | ||
| Q2 25 | $-111.7M | $-2.9M | ||
| Q1 25 | $-116.2M | $-2.9M | ||
| Q4 24 | — | $-22.4M | ||
| Q3 24 | $-83.5M | $-3.1M | ||
| Q2 24 | $-97.1M | $-2.6M | ||
| Q1 24 | $-113.0M | $-567.0K |
| Q4 25 | 67.4% | — | ||
| Q3 25 | 43.0% | — | ||
| Q2 25 | 5.5% | — | ||
| Q1 25 | -0.8% | — | ||
| Q4 24 | 68.7% | — | ||
| Q3 24 | 46.2% | — | ||
| Q2 24 | -0.8% | — | ||
| Q1 24 | — | — |
| Q4 25 | -84.7% | -17.7% | ||
| Q3 25 | -140.7% | -13.6% | ||
| Q2 25 | -189.8% | -5.9% | ||
| Q1 25 | -245.8% | -4.4% | ||
| Q4 24 | -117.5% | -33.1% | ||
| Q3 24 | -152.1% | -6.7% | ||
| Q2 24 | -327.6% | -5.5% | ||
| Q1 24 | -16464.6% | -2.2% |
| Q4 25 | — | -24.7% | ||
| Q3 25 | -135.3% | -15.8% | ||
| Q2 25 | -186.2% | -5.0% | ||
| Q1 25 | -235.5% | -4.6% | ||
| Q4 24 | — | -33.1% | ||
| Q3 24 | -142.7% | -4.3% | ||
| Q2 24 | -312.2% | -3.6% | ||
| Q1 24 | -15800.8% | -0.7% |
| Q4 25 | — | $-0.12 | ||
| Q3 25 | — | $-0.07 | ||
| Q2 25 | $-0.33 | $-0.02 | ||
| Q1 25 | $-0.36 | $-0.02 | ||
| Q4 24 | $-0.24 | $-0.18 | ||
| Q3 24 | $-0.28 | $-0.02 | ||
| Q2 24 | $-0.34 | $-0.02 | ||
| Q1 24 | $-0.42 | $0.00 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $297.0M | $104.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $698.6M | $227.9M |
| Total Assets | $913.2M | $290.6M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $297.0M | $104.9M | ||
| Q3 25 | $300.8M | $106.3M | ||
| Q2 25 | $301.2M | $112.9M | ||
| Q1 25 | $359.7M | $107.1M | ||
| Q4 24 | $323.8M | $109.2M | ||
| Q3 24 | $397.5M | $105.2M | ||
| Q2 24 | $412.5M | $106.3M | ||
| Q1 24 | $356.2M | $127.0M |
| Q4 25 | $698.6M | $227.9M | ||
| Q3 25 | $702.3M | $238.9M | ||
| Q2 25 | $698.5M | $245.3M | ||
| Q1 25 | $767.9M | $244.1M | ||
| Q4 24 | $710.4M | $244.7M | ||
| Q3 24 | $773.5M | $265.2M | ||
| Q2 24 | $768.5M | $263.6M | ||
| Q1 24 | $680.0M | $288.4M |
| Q4 25 | $913.2M | $290.6M | ||
| Q3 25 | $904.9M | $299.2M | ||
| Q2 25 | $907.4M | $316.2M | ||
| Q1 25 | $966.7M | $313.8M | ||
| Q4 24 | $910.4M | $323.0M | ||
| Q3 24 | $991.1M | $330.6M | ||
| Q2 24 | $964.3M | $333.4M | ||
| Q1 24 | $869.8M | $357.5M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-52.6M | $3.7M |
| Free Cash FlowOCF − Capex | $-61.9M | $3.6M |
| FCF MarginFCF / Revenue | -71.3% | 6.5% |
| Capex IntensityCapex / Revenue | 10.7% | 0.2% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-336.2M | $25.4M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-52.6M | $3.7M | ||
| Q3 25 | $-78.7M | $5.7M | ||
| Q2 25 | $-67.4M | $13.6M | ||
| Q1 25 | $-103.7M | $3.3M | ||
| Q4 24 | $-73.3M | $11.6M | ||
| Q3 24 | $-59.0M | $14.6M | ||
| Q2 24 | $-98.4M | $14.5M | ||
| Q1 24 | $-122.3M | $5.0M |
| Q4 25 | $-61.9M | $3.6M | ||
| Q3 25 | $-89.5M | $5.4M | ||
| Q2 25 | $-74.9M | $13.2M | ||
| Q1 25 | $-109.9M | $3.2M | ||
| Q4 24 | $-77.5M | $11.5M | ||
| Q3 24 | $-61.3M | $13.9M | ||
| Q2 24 | $-98.9M | $12.8M | ||
| Q1 24 | $-126.5M | $3.6M |
| Q4 25 | -71.3% | 6.5% | ||
| Q3 25 | -132.7% | 9.3% | ||
| Q2 25 | -124.9% | 22.3% | ||
| Q1 25 | -222.8% | 5.1% | ||
| Q4 24 | -105.1% | 16.9% | ||
| Q3 24 | -104.6% | 19.6% | ||
| Q2 24 | -317.9% | 17.6% | ||
| Q1 24 | -17685.3% | 4.6% |
| Q4 25 | 10.7% | 0.2% | ||
| Q3 25 | 16.1% | 0.5% | ||
| Q2 25 | 12.4% | 0.7% | ||
| Q1 25 | 12.6% | 0.2% | ||
| Q4 24 | 5.7% | 0.2% | ||
| Q3 24 | 3.9% | 0.9% | ||
| Q2 24 | 1.4% | 2.4% | ||
| Q1 24 | 583.4% | 1.9% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
IOVA
| Amtagvi | $64.9M | 75% |
| Proleukin | $21.9M | 25% |
MYPS
Segment breakdown not available.
